MAIA Biotechnology closes $695K private placement of stock and warrants for THIO-101 trial

MAIA Biotechnology, Inc.

Sold 463,332 shares and warrants at $1.50/share; warrants exercisable at $1.71, 5-year term, 6-month lockout.
Director Stan Smith purchased 33,333 shares and warrants for ~$50,000.
Gross proceeds ~$695,000; net proceeds to fund Step 1 of Part C of Phase II THIO-101 trial and working capital.
Expected closing May 29, 2025; securities exempt from registration under Section 4(a)(2)/Rule 506.

item 1.01item 3.02item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.